This review highlights that diabetic cardiomyopathy is driven by hyperglycemia and managed primarily through careful glycemic control and early neurohormonal antagonism.
Answers are grounded in this paper and cite their sources.
May support glycemic control plus early neurohormonal blockade in diabetic cardiomyopathy; leaves open need for dedicated prospective trials.
Diabetic cardiomyopathy is defined as the presence of myocardial dysfunction in patients with diabetes in the absence of coronary artery disease, hypertension, or other known cardiac disease. Diabetes has been shown to affect the heart through various cellular mechanisms leading to enhanced myocardial fibrosis, left ventricular hypertrophy, systolic and diastolic dysfunction. With increasing incidence of type II diabetes mellitus, it has continuously rising health and financial implications in both developed and developing countries. Hyperglycaemia seems to be the main deriving force, and careful glycaemic control as well as early administration of neurohormonal antagonists currently remains the mainstay of therapy. Many newer treatment targets are currently being explored. Here we present a brief review of its pathophysiology, association with heart failure symptoms, and management strategies.
No takes yet. Share an insight, caveat, or question.
Haq et al. (2013) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: